Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation

Onkologie

Volumn 35, Issue 11, 2012, Pages 658-664

  Then, Cornelia ^a   Hörauf, Natalie ^b   Otto, Sven ^c   Pautke, Christoph ^c   Von Tresckow, Emmo ^d   Röhnisch, Tim ^b   Baumann, Philipp ^b   Schmidmaier, Ralf ^b   Bumeder, Irmgard ^b   Oduncu, Fuat S ^b  

^a Department of Internal Medicine   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d NONE

Author keywords

Autologous stem cell transplantation; Bisphosphonate related osteonecrosis of the jaw; BRONJ; Multiple myeloma; ONJ

Indexed keywords

CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; DENTAL PROCEDURE; DOSE RESPONSE; DRUG SAFETY; FEMALE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RISK; RISK FACTOR; TREATMENT DURATION;

ADULT; AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RADIOTHERAPY, CONFORMAL; RISK FACTORS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84870000793     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000343950     Document Type: Article

References (46)

1. Ruggiero SL: Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 2011;1218:38-46.
2. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992;33:1657-1663.
3. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978.
4. Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T: Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 2010;14:35-41.
5. Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker D: Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 2010; 68:2837-2845.
6. Bartl R, Bartl C, Frisch B, Tresckow E von: Bisphosphonates in Medical Practice. Actions - Side Effects - Indications - Strategies. Berlin, Springer, 2007.
7. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A: Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002;(3): CD003188.
8. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramtzki M: The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010;126:239-246.
9. Rennert G, Pinchev M, Rennert HS, Gruber SB: Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011;29:1146-1150.
10. Rennert G, Pinchev M, Rennert HS: Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010;28:3577-3581.
11. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010;28:3582-3590.
12. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M: A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21:1545-1548.
13. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B: Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012;(5):CD003188.
14. Diel IJ, Bergner R, Grötz KA: Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5:475-482.
15. Marx RE: Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;6: 1115-1117.
16. Migliorati CA: Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21: 4253-4254.
17. Wang J, Goodger NM, Pogrel MA: Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-1107.
18. American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate- related osteonecrosis of the jaws: Advisory Task Force on Bisphosphonate- Related Ostenonecrosis of the Jaws. J Oral Maxillofac Surg 2007;65:369-376.
19. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SI, Shafer DM, Shum L, Silverman SI, van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
20. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009;35:119-130.
21. Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, Blum C, Grötz KA, Wagner W: Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 2010;6:11.
22. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
23. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sansville E, Ord R, Meiller T: Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-952.
24. Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
25. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF: Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 2011;1218:47-54.
26. Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, Pollastri G: Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007;48:56-64.
27. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580- 8587.
28. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionas K, Bamias A: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91:968-971.
29. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA: Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81:1047-1053.
30. IMWG: IMWG Guidelines for the Use of Bisphosphonates in Myeloma. myeloma. gr.jp/userfiles/file/medical-info/ID317-IMWG-BP-finished-E.pdf.
31. Jadu F, Lee L, Pharoah M, Reece D, Wang L: A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18:2015-2019.
32. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S: Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-1175.
33. Mawardi H, Giro G, Kajiya M, Ohta K, Almazrooa S, Alshwaimi E, Woo SB, Nishimura I, Kawai T: A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J Dent Res 2011;90:1339-1345.
34. Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-759.
35. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
36. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis- Papaiakovou E, Christoulas D, Terpos E, Bamias A: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-120.
37. Filleul O, Crompot E, Saussez S: Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136: 1117-1124.
38. Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85.
39. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garett-Sinha LA, Raghavan S: Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-847.
40. Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, Rizzoli R, Saffar JL, Samson I: Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 2009;45:843-852.
41. Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C: Bisphosphonate-related osteonecrosis of the jaws -Characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 2012;40:303-309.
42. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-1132.
43. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro- Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA: First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. National Cancer Research Institute Haematological Oncology Clinical Study Group. Lancet 2010;376:1989-1999.
44. Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro- Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE; National Cancer Research Institute Haematological Oncology Clinical Studies Group: Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 2011;12:743-752.
45. Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA; on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group: Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012;119:5374-5383.
46. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.